GnRH antagonists and endometrial receptivity in oocyte recipients: A prospective randomized trial

Reproductive BioMedicine Online

Volumn 18, Issue 2, 2009, Pages 276-281

  Prapas, Nikos ^a,b   Tavaniotou, Asimina ^b   Panagiotidis, Yannis ^b   Prapa, Stella ^b   Kasapi, Evangelia ^b   Goudakou, Maria ^b   Papatheodorou, Achilleas ^b   Prapas, Yannis ^a,b  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^b Iakentro Fertility Center   (Greece)

Author keywords

Endometrium; Implantation rate; IVF; Oocyte donation; Pregnancy rate

Indexed keywords

CHORIONIC GONADOTROPIN; ESTRADIOL; GANIRELIX; GONADORELIN ANTAGONIST; HUMAN MENOPAUSAL GONADOTROPIN;

ADULT; ARTICLE; CELL STIMULATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DONOR; DOUBLE BLIND PROCEDURE; ENDOMETRIUM; EVENING DOSAGE; FEMALE; FEMALE INFERTILITY; FERTILIZATION IN VITRO; HUMAN; INTRACYTOPLASMIC SPERM INJECTION; MAJOR CLINICAL STUDY; MENOPAUSE; NIDATION; OOCYTE DONATION; PREGNANCY RATE; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RECIPIENT;

EID: 60549110660     PISSN: 14726483     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1472-6483(10)60266-0     Document Type: Article

References (44)

1. Albano C, Felberbaum RE, Smitz J et al. 2000 Ovarian stimulation with HMG: results of a prospective randomized phase III European study comparing the luteinizing hormone-releasing hormone (LHRH)-a-ntagonist cetrorefix and the LHRH-agonist buserelin. European Cetrorelix Study Group. Human Reproduction 15, 526-531.
2. Albano C, Smitz J, Camus M et al. 1997 Comparison of different doses of gonadotropin-releasing hormone antagonist Cetrorelix during controlled ovarian hyperstimulation. Fertility and Sterility 67, 917-922.
3. Al-Inany H and Aboulghar M 2002 GnRH antagonist in assisted reproduction: a Cochrane review. Human Reproduction 17, 874-885.
4. Bassil S 2001 Changes in endometrial thickness, width, length and pattern in predicting pregnancy outcome during ovarian stimulation in IVF. Ultrasound in Obstetrics and Gynecology 18, 258-263.
5. Borm G, Mannaerts B 2000 Treatment with the gonadotrophin-releasing hormone antagonist ganirelix in women undergoing ovarian stimulation with recombinant follicle stimulating hormone is effective, safe and convenient: results of a controlled, randomized, multicentre trial. The European Orgalutran Study Group. Human Reproduction 15, 1490-1498.
6. Bosch E, Valencia I, Escudero E et al. 2003 Premature luteinization during gonadotropin-releasing hormone antagonist cycles and its relationship with in-vitro fertilization outcome. Fertility and Sterility 80, 1444-1449.
7. Check JH, Nowroozi K, Choe J et al. 1991 Influence of endometrial thickness and echo patterns on pregnancy rates during in-vitro fertilization. Fertility and Sterility 56, 1173-1175.
8. Cobo A, Bosch E, Alvarez C, de los Santos MJ et al. 2007 Effect of a sharp serum oestradiol fall before HCG administration during ovarian stimulation in donors. Reproductive BioMedicine Online 15, 169-174
9. De Geyter C, Schmitter M., De Geyter M et al. 2000 Prospective evaluation of the ultrasound appearance of the endometrium in a cohort of 1186 infertile women. Fertility and Sterility 73, 106-113.
10. Dekel N, Lewysolm O, Ayalon D et al. 1988 Receptors for gonadotropin releasing hormone are present in rat oocytes. Endocrinology 123, 1205-1207.
11. Dong KW, Marcelin K, Hsu MI et al. 1998 Expression of gonadotropin-releasing hormone (GnRH) gene in human uterine endometrial tissue. Molecular Human Reproduction 4, 893-898.
12. Fauser BCJM, Devroey P 2005 Why is the clinical acceptance of gonadotropin releasing hormone antagonist co-treatment during ovarian hyperstimulation for in-vitro fertilization so slow? Fertility and Sterility 83, 1607-1611.
13. Filicori M, Cognigni GE, Tabarelli C et al. 2002 Stimulation and growth of antral ovarian follicles by selective LH activity administration in women. Journal of Clinical Endocrinology and Metabolism 87, 1156-1161.
14. Filicori M, Cognigni GE, Taraborrelli S et al. 2001 Luteinizing hormone activity in menotropins optimizes folliculogenesis and treatment in controlled ovarian stimulation. Journal of Clinical Endocrinology and Metabolism 86, 337-343.
15. Gründker C, Schlotawa L, Viereck V et al. 2004 Antiproliferative effects of the GnRH antagonist cetrorelix. and of GnRH-II on human endometrial and ovarian cancer cells ate not mediated through the GnRH type I receptor. European Journal of Endocrinology 151, 141-149.
16. Hernandez ER 2000 Embryo implantation and GnRH antagonists; embryo implantation: the Rubicon for GnRH antagonists. Human Reproduction 15, 1211-1216.
17. Hohmann FP, Macklon NS, Fauser BC 2003 A randomized comparison of two ovarian stimulation protocols with gonadotropin-releasing hormone (GnRH) antagonist cotreatment for in-vitro fertilization commencing recombinant follicle-stimulating hormone on cycle day 2 or 5 with the standard long GnRH agonist protocol. Journal of Clinical Endocrinology and Metabolism 88, 166-173.
18. Ikeda M, Taga M, Kurogi K et al. 1997 Gene expression of gonadotropin-releasing hormone, but not its receptor, in human endometrium and decidua. Molecular and Cellular Endocrinology 135, 165-168.
19. Kane MT, Morgan PM, Coonan C 1997 Peptide growth factors and preimplantation development. Human Reproduction Update 3, 137-157.
20. Kol S, Lightman A, Hillensjo T et al. 1999 High doses of gonadotrophin-releasing hormone antagonist in in-vitro fertilization cycles do not adversely affect the outcome of subsequent freeze-thaw cycles. Human Reproduction 14, 2242-2244.
21. Kolibianakis EM, Collins J, Tarlatzis BC et al. 2006 Among patients treated for IVF with gonadotrophins and GnRH analogues, is the probability of live birth dependent on the type of analogue used? A systematic review and meta-analysis. Human Reproduction Update 12, 651-671.
22. Kolibianakis EM, Zikopoulos K, Schiettecatte I et al. 2004 Profound LH suppression after GnRH antagonist administration is associated with a significantly higher ongoing pregnancy rate in IVF. Human Reproduction 19, 2490-2496.
23. Kolibianakis EM, Bourgain C, Platteau P et al. 2003 Abnormal endometrial development occurs during the luteal phase of non supplemented donor cycles treated with recombinant follicle-stimulating hormone and gonadotropin-releasing hormone antagonists. Fertility and Sterility 80, 464-466.
24. Minaretzis D, Jakubowski M, Mortola JF et al. 1995 Gonadotropin-releasing hormone receptor gene expressionin human ovary and granulosa-lutein cells. Journal of Clinical Endocrinology and Metabolism 80, 430-434.
25. Noyes N, Liu HC, Sultan K, Schattman G et al. 1995 Endometrial thickness appears to be a significant factor in embryo implantation in IVF. Human Reproduction 10, 919-922.
26. Ortmann O, Weiss JM, Diedrich K 2001 Embryo implantation and GnRH antagonists: ovarian actions of GnRH antagonists. Human Reproduction 16, 608-611.
27. Papanikolaou EG, Bourgain C, Kolibianakis E et al. 2005 Steroid receptor expression in late follicular phase endometrium in GnRH antagonist IVF cycles is already altered, indicating initiation of early luteal phase transformation in the absence of secretory changes. Human Reproduction 20, 1541-1547.
28. Polak de Fried E, Divita AE, Chmielewski M et al. 2004 Effect of a single dose of GnRH antagonist on the endometrial thickness. Fertility and Sterility 82, S193.
29. Prapas N, Prapas Y, Panagiotidis Y et al. 2005 GnRH agonist versus GnRH antagonist in oocyte donation cycles; a prospective randomized study. Human Reproduction 20, 1516-1520.
30. Prapas N, Prapas Y, Panagiotidis Y et al. 2004 Cervical dilatation has a positive impact on the outcome of IVF in randomly assigned cases having two previous difficult embryo transfers. Human Reproduction 19, 1791-1795.
31. Prapas Y, Prapas N, Hatziparasidou A et al. 1995 The echo guide embryo transfer maximizes the IVF results. Acta Europaea Fertilitatis 26, 113-115.
32. Raga F, Casañ EM, Kruessel J et al. 1999 The role of gonadotropin-releasing hormone in murine preimplantation embryonic development. Endocrinology 140, 3705-3712.
33. Raga F, Casañ EM, Kruessel JS et al. 1998 Quantitative gonadotropin-releasing hormone gene expression and immunohistochemical localization in human endometrium throughout the menstrual cycle. Biology of Reproduction 59, 661-669.
34. Rinaldi L, Lisi F, Floccari A et al. 1996 Endometrial thickness as a predictor of pregnancy after in-vitro fertilization but not after ICSI. Human Reproduction 11, 1538-1541.
35. Sauer MV, Paulson RJ, Lobo RA 1997 Comparing the clinical utility of GnRH antagonist to GnRH agonist in an oocyte donation program. Gynecologic and Obstetric Investigation 43, 215-218.
36. Simon C, Oberyé J, Bellver J et al. 2005 Similar endometrial development in oocyte donors treated with either high- or standard-dose GnRH antagonist compared to treatment with a GnRH agonist or in natural cycles. Human Reproduction 20, 3318-3327.
37. Takeuchi S, Futamura N, Minoura H et al. 1998 Possible direct effect of gonadotropin releasing hormone on human endometrium and deciduas. Life Science 62, 1197-1194.
38. Tarlatzis BC, Fauser BC, Kolibianakis EM et al. on behalf of the Brussels GnRH Antagonist Consensus Workshop Group 2006 GnRH antagonists in ovarian stimulation for IVF. Human Reproduction Update 12, 333-340.
39. Tavaniotou A, Albano C, Van Steirteghem A et al. 2003 The impact of LH serum concentration on the clinical outcome of IVF cycles in patients receiving two regimens of clomiphene citrate/gonadotrophin/0.25 mg cetrorelix. Reproductive BioMedicine Online 6, 421-426.
40. Tesarik J, Hazout A, Mendoza C 2003 Luteinizing hormone affects uterine receptivity independently of ovarian function. Reproductive BioMedicine Online 7, 59-64.
41. The Ganirelix Dose-Finding Study Group 1998 A double-blind, randomized, dose-finding study to assess the efficacy of the gonadotrophin-releasing hormone antagonist ganirelix (Org 37462) to prevent premature luteinizing hormone surges in women undergoing ovarian stimulation with recombinant follicle stimulating hormone (Puregon). Human Reproduction 13, 3023-3031.
42. Vani S, McDonald SE, Williams AR et al. 2007 Mid-luteal endometrial intracrinology following controlled ovarian hyperstimulation involving use of a gonadotrophin releasing hormone antagonist. Human Reproduction 22, 2981-2991.
43. Vlahos NF, Bankowski BJ, Zacur HA et al. 2005 An oocyte donation protocol using the GnRH antagonist ganirelix acetate, does not compromise embryo quality and is associated with high pregnancy rates. Archives of Gynecology and Obstetrics 272, 1-6.
44. Yuval Y, Lipitz S, Dot J, Achiron R 1999 The relationship between endometrial thickness, and blood flow and pregnancy rates in IVF. Human Reproduction 14, 1067-1071.